Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT02989857 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.

NCT NCT02989857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02989857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Lead sponsor
Institut de Recherches Internationales Servier
Phase
Phase 3
Overall status
Completed
Start date
February 20, 2017
Completion date
May 17, 2021
Enrollment
187 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cholangiocarcinoma, metastatic cholangiocarcinoma